Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 5/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754116 | 1.00 | ESR1 (0.72) | ESR1ESR2NR1H2PKMABHD6 | |
| Hydrochloric Acid SCHEMBL1639774 | 0.99 | ESR1 (0.70) | ESR1ESR2NR1H2PKMABHD6 | |
| SCHEMBL4179872 | 0.94 | ESR2 (0.72) | ESR1ESR2NR1H2PKMABHD6 | |
| SCHEMBL3353692 | 0.92 | ESR1 (0.60) | ESR1ESR2NR1H2PKMABHD6 | |
| SCHEMBL373718 | 0.91 | ESR1 (0.58) | ESR1ESR2NR1H2PKMABHD6 | |
| SCHEMBL5913288 | 0.88 | ESR1 (0.54) | ESR1ESR2NR1H2ABHD6HDAC6 | |
| SCHEMBL29986831 | 0.88 | ESR1 (0.54) | ESR1ESR2NR1H2ABHD6HDAC6 | |
| SCHEMBL4183920 | 0.84 | ESR1 (0.74) | ESR1ESR2PKMABHD6MERTK | |
| SCHEMBL28947577 | 0.83 | ESR1 (0.52) | ESR1ESR2NR1H2PKMABHD6 | |
| SCHEMBL3865684 | 0.82 | ESR1 (0.72) | ESR1ESR2PKMABHD6MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-07-31 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4079726-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| WO-2003068732-A2 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 AND D2 RECEPTOR LIGA DS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-6248754-B1 | PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2001-06-19 | — | — | US | disclosed |
| EP-1042296-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-11 | — | — | EP | disclosed |
| US-6110934-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-1005459-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-2000007993-A1 | SUBSTITUTED ISOQUINOLEINES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999031068-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
| EP-0906283-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | ESR1 3000/4885ESR2 2354/4885NR1H2 3897/4885 |
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | ESR1 3377/4885ESR2 1845/4885NR1H2 911/4885 |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | ESR1 4638/4885ESR2 4460/4885NR1H2 2592/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | ESR1 4638/4885ESR2 4460/4885NR1H2 2592/4885 |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | ESR1 3377/4885ESR2 1845/4885NR1H2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.